DP
OVID icon

Diadema Partners’s Ovid Therapeutics OVID Stock Holding History

Diadema Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-187,739
Closed -$244K – 179
2025
Q3 		$244K Buy
+187,739
New +$163K 0.06% 113

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Diadema Partners's OVID Position: Q4 2025 in Review

Diadema Partners sold out of Ovid Therapeutics (OVID) in Q4 2025, closing a stake of 187,739 shares — an estimated $244K sold.

Diadema Partners first reported a position in OVID in Q3 2025 and held it in 1 quarter. The position peaked at $244K in Q3 2025. 84 funds tracked by Wall St. Rank hold OVID as of Q4 2025.

  • Diadema Partners reported no remaining Ovid Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 187,739 Ovid Therapeutics shares in Q4 2025, an estimated $244K.
  • Diadema Partners first reported a position in Ovid Therapeutics in Q3 2025 and held it in 1 quarter.
  • Diadema Partners's Ovid Therapeutics position peaked at $244K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.